AAA
CNTX icon

Affinity Asset Advisors’s Context Therapeutics CNTX Stock Holding History

Affinity Asset Advisors’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-402,653
Closed -$390K – 99
2025
Q3 		$390K Sell
402,653
-115,372
-22% -$93.5K 0.03% 90
2025
Q2 		$339K Sell
518,025
-142,564
-22% -$103K 0.05% 80
2025
Q1 		$404K Sell
660,589
-354,751
-35% -$309K 0.04% 86
2024
Q4 		$1.07M Sell
1,015,340
-305,813
-23% -$529K 0.14% 69
2024
Q3 		$2.59M Sell
1,321,153
-297,987
-18% -$661K 0.35% 61
2024
Q2 		$3.25M Buy
1,619,140
+1,290,323
+392% +$2.22M 0.37% 54
2024
Q1 		$454K Hold
328,817
– – 0.06% 90
2023
Q4 		$372K Hold
328,817
– – 0.07% 78
2023
Q3 		$497K Buy
328,817
+61,243
+23% +$69.3K 0.14% 73
2023
Q2 		$428K Buy
+267,574
New +$228K 0.15% 67
2023
Q1 		– Sell
-883,654
Closed -$584K – 77
2022
Q4 		$584K Hold
883,654
– – 0.23% 56
2022
Q3 		$981K Hold
883,654
– – 0.27% 51
2022
Q2 		$1.87M Buy
883,654
+106,044
+14% +$199K 0.79% 32
2022
Q1 		$1.69M Buy
+777,610
New +$1.64M 0.27% 43

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Affinity Asset Advisors's CNTX Position: Q4 2025 in Review

Affinity Asset Advisors sold out of Context Therapeutics (CNTX) in Q4 2025, closing a stake of 402,653 shares — an estimated $390K sold.

Affinity Asset Advisors first reported a position in CNTX in Q1 2022 and held it in 14 quarters. The position peaked at $3.25M in Q2 2024. 42 funds tracked by Wall St. Rank hold CNTX as of Q4 2025.

  • Affinity Asset Advisors reported no remaining Context Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 402,653 Context Therapeutics shares in Q4 2025, an estimated $390K.
  • Affinity Asset Advisors first reported a position in Context Therapeutics in Q1 2022 and held it in 14 quarters.
  • Affinity Asset Advisors's Context Therapeutics position peaked at $3.25M in Q2 2024.
  • 42 funds tracked by Wall St. Rank held Context Therapeutics as of Q4 2025.

Based on Affinity Asset Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.